AU2020210930B2 - GPR35 modulators - Google Patents

GPR35 modulators

Info

Publication number
AU2020210930B2
AU2020210930B2 AU2020210930A AU2020210930A AU2020210930B2 AU 2020210930 B2 AU2020210930 B2 AU 2020210930B2 AU 2020210930 A AU2020210930 A AU 2020210930A AU 2020210930 A AU2020210930 A AU 2020210930A AU 2020210930 B2 AU2020210930 B2 AU 2020210930B2
Authority
AU
Australia
Prior art keywords
6alkyl
solvate
compound
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020210930A
Other languages
English (en)
Other versions
AU2020210930A1 (en
Inventor
Robert Higuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometheus Biosciences Inc
Original Assignee
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometheus Biosciences Inc filed Critical Prometheus Biosciences Inc
Publication of AU2020210930A1 publication Critical patent/AU2020210930A1/en
Application granted granted Critical
Publication of AU2020210930B2 publication Critical patent/AU2020210930B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020210930A 2019-01-24 2020-01-23 GPR35 modulators Active AU2020210930B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (2)

Publication Number Publication Date
AU2020210930A1 AU2020210930A1 (en) 2021-09-09
AU2020210930B2 true AU2020210930B2 (en) 2025-08-14

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020210930A Active AU2020210930B2 (en) 2019-01-24 2020-01-23 GPR35 modulators

Country Status (13)

Country Link
US (2) US11053251B2 (cg-RX-API-DMAC7.html)
EP (1) EP3914256B1 (cg-RX-API-DMAC7.html)
JP (1) JP7588077B2 (cg-RX-API-DMAC7.html)
KR (1) KR102863894B1 (cg-RX-API-DMAC7.html)
CN (1) CN113631168B (cg-RX-API-DMAC7.html)
AU (1) AU2020210930B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021014566A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127786A1 (cg-RX-API-DMAC7.html)
IL (1) IL285074B2 (cg-RX-API-DMAC7.html)
MA (1) MA54825A (cg-RX-API-DMAC7.html)
MX (1) MX2021008941A (cg-RX-API-DMAC7.html)
TW (1) TWI845600B (cg-RX-API-DMAC7.html)
WO (1) WO2020154492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
AR123034A1 (es) * 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
FR2845993B1 (fr) * 2002-10-16 2005-02-11 Univ Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques
WO2005085867A2 (en) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
AU2012262021B2 (en) 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
CA3168304A1 (en) 2014-06-29 2016-01-07 Profile Products L.L.C. Bark and wood fiber growing medium
US10626180B2 (en) 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CA3128942A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
JP2022519819A (ja) 2019-02-08 2022-03-25 シーダーズ―シナイ メディカル センター Il18r1を標的とする炎症性疾患を処置するための方法、システム、およびキット
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
AR123034A1 (es) 2020-07-23 2022-10-26 Prometheus Biosciences Inc Agentes terapéuticos dirigidos a gpr35
IL302791A (en) 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4263585A4 (en) 2020-12-21 2024-11-27 Cedars-Sinai Medical Center THERAPEUTIC COMPOSITIONS OF TL1A AND METHODS OF TREATMENT USING THEM

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURA JENKINS ET AL: "Antagonists of GPR35 Display High Species Ortholog Selectivity and Varying Modes of Action", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 343, no. 3, 11 September 2012 (2012-09-11), pages 683 - 695 *

Also Published As

Publication number Publication date
EP3914256B1 (en) 2024-05-29
US20200239476A1 (en) 2020-07-30
US11773101B2 (en) 2023-10-03
MX2021008941A (es) 2021-10-13
IL285074A (en) 2021-09-30
CN113631168A (zh) 2021-11-09
EP3914256A1 (en) 2021-12-01
US20210380590A1 (en) 2021-12-09
US11053251B2 (en) 2021-07-06
TW202043234A (zh) 2020-12-01
TWI845600B (zh) 2024-06-21
BR112021014566A2 (pt) 2022-01-04
IL285074B1 (en) 2024-08-01
AU2020210930A1 (en) 2021-09-09
CA3127786A1 (en) 2020-07-30
WO2020154492A1 (en) 2020-07-30
JP7588077B2 (ja) 2024-11-21
CN113631168B (zh) 2024-11-19
EP3914256A4 (en) 2022-09-28
JP2022518523A (ja) 2022-03-15
MA54825A (fr) 2021-12-01
KR102863894B1 (ko) 2025-09-23
IL285074B2 (en) 2024-12-01
KR20210119485A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
US11884680B2 (en) Bromodomain inhibitors
AU2017201076B2 (en) Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
KR102030305B1 (ko) 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물
EP3027616B1 (en) Azaindole compounds as modulators of rorc
KR102863894B1 (ko) Gpr35 조절제
KR20170045308A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 이미다조[1,2-a]피리딘 유도체
AU2019291490B2 (en) Cyanotriazole compounds and uses thereof
US20230151017A1 (en) Therapeutic agents targeting gpr35
KR20180025928A (ko) 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체
JP2023545452A (ja) クリプトスポリジウム症の治療のための化合物及び組成物
EA048936B1 (ru) Модуляторы gpr35
WO2025064325A1 (en) Gpr35 modulators
HK40059523A (en) Gpr35 modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)